News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Jan Geissler Addressing the Patient’s Perspective at the 6th EORTC Quality of Life Conference
Jan Geissler/LinkedIn
May 13, 2025, 17:14

Jan Geissler Addressing the Patient’s Perspective at the 6th EORTC Quality of Life Conference

EORTC Quality of Life Group (QLG) shared on X:

“Patient-reported outcome (PRO) data is essential to understand cancer patients’ reality – Jan Geissler addressing the patient’s perspective at the 6th EORTC Quality of Life conference.”

Jan Geissler

More posts featuring EORTC Quality of Life Group.

cancer EORTC eortc qlg OncoDaily Oncology patient-reported outcome
Special Coverage
Blog
Aug 4, 2025, 22:44
Let’s Connect Across Disciplines to Shape the Future of Pediatric Oncology Together - SIOP
Blog
Aug 4, 2025, 20:57
What Happens to the Donations and Sponsorships Received? - Dăruiește Viață
Career
Aug 4, 2025, 20:46
Honoring Julie Gralow’s Lifetime Achievement Award from India’s National Cancer Grid
Blog
Aug 4, 2025, 20:45
Why Cancer Prevention Must be Treated as a Global Systems Risk - IARC
Science
Aug 4, 2025, 20:39
Scott Kopetz: Hunting for the Very Rare Clonal Fusions for Clinical Benefit
Blog
Aug 4, 2025, 20:38
Radhakrishna Pillai: Remembering Dr. R. Sankaranarayanan - A Titan of Cancer Prevention
Blog
Aug 4, 2025, 20:36
Patty Spears: Building Trust and Fostering Communication Directly with Researchers Matters
Blog
Aug 4, 2025, 20:35
The Recipients of the 2025 Cervical Screening Community Engagement Grants - Cancer Institute NSW
Blog
Aug 4, 2025, 20:31
IACH Post-ASCO and EHA 2025 Webinar Highlights
Science
Aug 4, 2025, 20:27
Nikolas Stoecklein: Circulating Tumor Cells Are Still Alive
Blog
Aug 4, 2025, 20:19
Honoring the Legacy of Dr. Rengaswamy Sankaranarayanan - IARC/WHO
Science
Aug 4, 2025, 20:16
Tanja Obradovic: Jaypirca vs Imbruvica - Promising Phase 3 Data in CLL/SLL